Early-life Oxytocin treatment reduces audiogenic seizures in male Fragile X syndrome model mice
Background
Fragile X syndrome (FXS) is the leading inherited cause of intellectual disability, frequently accompanied by seizures, which significantly impact quality of life. Current treatments for FXS primarily manage symptoms, but lack disease-modifying effects, especially for seizure susceptibility. Oxytocin (OXT) has shown promise in improving social behavior and cognitive function in rodent models of autism spectrum disorders (ASD) and FXS, suggesting a potential broader therapeutic role. However, OXT's effects on seizure susceptibility, a critical comorbidity in FXS, have remained largely unexplored, representing a significant gap in understanding its full therapeutic potential.
Study Design
Researchers investigated the effect of early-life intranasal oxytocin (iOXT) on audiogenic seizures (AGS) in Fmr1 -Knockout (KO) mice, a model for FXS. Male and female Fmr1 -KO mice received daily iOXT or saline (iSAL) from postnatal day (P) 7 to P13. A separate cohort received iOXT from P30 to P36 to assess age-dependency. The primary endpoint was the incidence, severity, and latency to seize during AGS testing in adulthood. Acute OXT effects were also tested in adult males 30-60 min, 1 day, and 15 days post-treatment.
Results
Early-life iOXT treatment significantly reduced seizure susceptibility in adult male Fmr1 -KO mice. Daily iOXT from P7 to P13 significantly reduced the incidence and severity of AGS and increased the latency to seize in adult male Fmr1 -KOs. Female Fmr1 -KOs exhibited less severe seizures overall, which were notably unaffected by iOXT treatment, highlighting a marked sex difference. Wild-type mice did not exhibit AGS regardless of treatment. The antiepileptic effects of iOXT were found to be age-dependent; male Fmr1 -KOs receiving later treatments (P30 to P36) exhibited robust seizures comparable between OXT- and SAL-treated groups. This suggests that OXT's enduring antiepileptic benefits are confined to early postnatal treatments. Acute OXT administration in adulthood attenuated male Fmr1 -KO AGS at 30-60 min and 1 day post-treatment, but these effects were not evident 15 days later. This indicates a transient acute effect distinct from the enduring benefits of early-life intervention.
Early-life intranasal oxytocin treatment from P7-P13 significantly reduced audiogenic seizure incidence and severity in adult male Fmr1-KO mice.
Key Findings
- Early-life iOXT (P7-P13) significantly reduced
AGSincidence and severity in adult maleFmr1 -KOmice. - Female
Fmr1 -KOmice had less severe seizures, which were unaffected by iOXT treatment. - Later iOXT treatment (P30-P36) did not reduce
AGSin maleFmr1 -KOmice, indicating age-dependency. - Acute OXT in adulthood attenuated
AGSfor1 day, but effects were not sustained15 dayslater.
Why It Matters
Early-life oxytocin treatment could offer a novel, sex-specific therapeutic strategy for mitigating seizure susceptibility in male Fragile X syndrome patients. This research identifies a critical developmental window (second postnatal week) for OXT intervention to achieve lasting antiepileptic effects, suggesting that timing is paramount for clinical translation. For individuals with FXS, particularly males, this opens avenues for early, targeted interventions that could reduce the burden of seizures, potentially improving long-term neurological outcomes. The findings underscore the importance of considering sex differences in treatment protocols and highlight that acute OXT effects differ significantly from enduring developmental programming. Future clinical trials would need to carefully consider patient age and sex, moving towards a precision medicine approach for FXS.
oxytocin
fragile-x-syndrome
seizures
neurodevelopmental
preclinical-animal
sex-differences